Lexaria begins biodistribution study for DehydraTECH GLP-1
Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Whose cardiovascular health do SGLT2, GLP-1 diabetes drugs benefit most?
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
Medscape7h
Some Patients — And Doctors — Turn to Microdosing GLP-1s
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
Healio21h
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...